Aldeyra Therapeutics, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Aldeyra Therapeutics, Inc.  (NASDAQ: ALDX) between March 17, 2022 and June 20, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 29, 2023.

If you purchased Aldeyra securities during the Class Period and would like to join the action, please click “Join This Class Action.”

Class Period:March 17, 2022 through June 20, 2023
If you purchased Aldeyra. securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of the case:

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:

  • the new drug application (“NDA”) for ADX-2191 (a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss) did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191’s effectiveness;
  • as a result, the U.S. Food and Drug Administration (“FDA”) was unlikely to approve the ADX-2191 NDA in its current form;
  • accordingly, Aldeyra had overstated ADX-2191’s clinical and/or commercial prospects; and
  • as a result, Aldeyra’s public statements were materially false and misleading at all relevant times.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Follow us on:
Company Name: Aldeyra Therapeutics, Inc.
Stock Symbol: ALDX
Class Period: March 17, 2022 through June 20, 2023
Court: United States District Court for the District of Massachusetts

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top